Patient adherence to evidence‐based pharmacotherapy in systolic heart failure and the transition of follow‐up from specialized heart failure outpatient clinics to primary care
Open Access
- 1 June 2013
- journal article
- Published by Wiley in European Journal of Heart Failure
- Vol. 15 (6), 671-678
- https://doi.org/10.1093/eurjhf/hft011
Abstract
Aims Undertreatment with evidence‐based pharmacotherapy for heart failure (HF) is an important problem, and it has been suggested that specialized HF clinics (HFCs) can improve treatment initiation and correct dosing. The objective of this study was to examine long‐term adherence to and dosages of evidence‐based pharmacotherapy during and after participation in specialized HFCs. Methods and results Initiation, dosages, and adherence were studied in patients with systolic HF attending HFCs in Denmark from 2002 to 2009. Information was obtained from an electronic patient file and research database used in the HFCs combined with prescription data from the Danish Registry of Medicinal Product Statistics. A total of 8792 patients were included in the study. The mean age was 68 years; with a mean LVEF of 30%, and 72% were males. Long‐term adherence to treatment was high for the patients who initiated renin–angiotensin system (RAS) inhibitors and beta‐blockers. Adherence after 1 year was 93% for RAS inhibitors, 92% for beta‐blockers, and 86% for spironolactone. After 3 years, it was 90% for RAS inhibitors, 88% for beta‐blockers, and 74% for spironolactone. For patients referred back to their general practitioner (GP), adherence 1 year after they left the HFC was 89% for RAS inhibitors, 89% for beta‐blockers, and 72% for spironolactone. Conclusion In specialized outpatient HFCs, long‐term adherence to RAS inhibitors and beta‐blockers is close to optimal. Importantly, adherence was maintained after patients were referred back to their GP for continued management. This is likely to provide long‐term benefits for the patients.This publication has 28 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012European Journal of Heart Failure, 2012
- Aliskiren, ALTITUDE, and the implications for ATMOSPHEREEuropean Journal of Heart Failure, 2012
- Characteristics, Implementation of Evidence-Based Management and Outcome in Patients with Chronic Heart Failure Results from the Norwegian Heart Failure RegistryEuropean Journal of Cardiovascular Nursing, 2011
- Self‐care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2011
- Characteristics and in-hospital outcomes for nonadherent patients with heart failure: Findings from Get With The Guidelines-Heart Failure (GWTG-HF)American Heart Journal, 2009
- Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure studyHeart, 2006
- Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective studyBMJ, 2003
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987